Costs and effects of prostate cancer screening in Sweden
A 15-year follow-up of a randomized trial

References

• The National Board of Health and Welfare Cancer incidence in Sweden 1999. Health and Diseases No. 2001: 4. Stockholm: The National Board of Health and Welfare, 2001.
   Google Scholar
• The National Board of Health and Welfare. Folkhälsan i siffror. www. 50 5. se/sos/stat.htm.
   Google Scholar
• Schroder FH, Kranse R, Riebergen J, Hoedemaeke R, Krikels W. The European Randomized Study of Screen-ing for Prostate Cancer (ERSPC): an update. Members of the ERSPC, Section Rotterdam. Eur Urol 1999; 35: 539–43.
   Google Scholar
• Holmberg L, Bill-Axelsson A, Helgesen F, Salo JO, Folmerz P. Häggman M, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347: 781–9.
   Google Scholar
• Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, et al. Cancer surveillance series: interpreting trends in prostate cancer. Part 1: evidence of the effects of screening in recent prostate cancer incidence, mor-tality and survival rates. J Natl Cancer Inst 1999; 91: 1017–24.
   Google Scholar
• Gilliland FD, Hunt WC, Key CR. Improving survival for patients with prostate cancer diagnosed in the prostate-specific antigen era. Urology 1996; 48: 67–71.
   Google Scholar
• Bartsch G, Hominger W, Klocker H, Reissigl A, Oberaigner W, Schönitzer D, et al. Prostate cancer mor-tality after introduction of prostate-specific antigen mass screening in the federal state of Tyrol, Austria. Urology 2001; 58: 417–24.
   Google Scholar
• de Koning HJ, Auvinen A, Sanchez Berenguer A, Calais da Silva F, Ciatto S, Denis L, et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colo-rectal and Ovary cancer trial. Int J Cancer 2002; 97: 237–44.
   Google Scholar
• Bjurstam N, Bjömeld L, Duffy SW, Smith TC, Cahlin E, Eriksson O. The Gothenburg Breast Screening Trial. Cancer 1997; 80: 2091–9.
   PubMed Web of Science ®Google Scholar
• Alexander FE, Anderson TJ, Brown HK, Forrest APM, Hepburn W, Kirkpatrick AE. 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screen-ing. Lancet 1999; 353: 1903–8.
   PubMed Web of Science ®Google Scholar
• Andersson I, Aspegren K, Janzon L, Landberg T, Lindholm K, Linell F. Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial. Br Med J 1988; 297: 943–8.
   PubMed Web of Science ®Google Scholar
• UK Trial of Early Detection of Breast Cancer group. 16-year mortality from breast cancer in the UK Trial of Early Detection of Breast Cancer. Lancet 1999; 353: 1909–14.
   Google Scholar
• Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer. JAMA 1997; 277: 467–71.
   Google Scholar
• Adolfsson J, Steineck G, Hedlund PO. Deferred treat-ment of clinically localized low-grade prostate cancer: actual 10-year and projected 15-year follow-up of the Karolinska series. Urology 1997; 50: 722–6.
   Google Scholar
• Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 242–8.
   PubMed Web of Science ®Google Scholar
• Sandblom G, Dufmats M, Varenhorst E. Long-term survival in a Swedish population-based cohort of men with prostate cancer. Urology 2000; 56: 442–7.
   Google Scholar
• Pedersen KV, Carlsson P. Varenhorst E, Löfman O, Berglund K. Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. Br Med J 1990; 300: 1041–4.
   Google Scholar
• Carlsson P. Pedersen KV, Varenhorst E. Costs and benefits of early detection of prostate cancer. Health Policy 1990; 16: 241–53.
   Google Scholar
• Varenhorst E, Pedersen KV, Carlsson P. Berglund K, Löfman O. Screening for carcinoma of the prostate in a randomly selected population using duplicate digital rectal examination. Acta Oncol 1991; 30: 273–5.
   Google Scholar
• Varenhorst E, Carlsson P. Capik E, Löfman O, Pedersen Ky. Repeated screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. Acta Oncol 1992; 31: 815–21.
   Google Scholar
• Varenhorst E, Pedersen KV, Carlsson P. Berglund K, Löfman O. Screening for carcinoma of the prostate in a randomly selected population. Recent Results Cancer Res 1993; 126: 25–30.
   Google Scholar
• Holmberg H, Carlsson P. Löfman O, Varenhorst E. Economic evaluation of screening for prostate cancer: a randomized population based programme during a 10-year period in Sweden. Health Policy 1998; 45: 133–47.
   Google Scholar
• Sandblom G, Dufmats M, Olsson M, Varenhorst E. Validity of a population-based cancer register in Sweden. An assessment of data reproducibility in the South-East Region Prostate Cancer Register. Scand J Urol Nephrol 2003; 37: 112–9.
   Google Scholar
• Sennfält K, Carlsson P. Thorfinn J, Frisk J, Henriksson M, Varenhorst E. Technological changes in the Scand J Urol Nephrol management of prostate cancer result in increased health-care costs. Scand J Urol Nephrol 2003; 37: 226–31.
   Google Scholar
• Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, et al. Lead times and over-detection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868–78.
   Google Scholar
• McGregor M, Hanley JA, Boivin JF, McLean RG. Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 1998; 159: 1368–72.
   PubMed Web of Science ®Google Scholar
• Ciatto S, Zappa M, Bonardi R, Gervasi G. Prostate cancer screening: the problem of overdiagnosis and lessons to be learned from breast cancer screening. Eur J Cancer 2000; 36: 1347–50.
   PubMed Web of Science ®Google Scholar
• Rationale for randomised trials of prostate cancer screening. The International Prostate Screening Trial Evaluation Group. Eur J Cancer 1999; 35: 262–71.
   PubMedGoogle Scholar
• Lefevre ML. Prostate cancer screening: more harm than good? Am Fam Physician 1998; 58: 432–8.
   PubMed Web of Science ®Google Scholar
• Maattanen L, Auvinen A, Stenman U-H, Rannikko S, Tammela T, Aro J, et al. European randomized study of prostate cancer screening: first-year results of the Finnish trial. Br J Cancer 1999; 79: 1210–4.
   Google Scholar
• Cookson M. Prostate cancer: screening and early detec-tion. Cancer Control 2001; 8: 133–40.
   PubMedGoogle Scholar
• Bunting P. Screening for prostate cancer with prostate-specific antigen: beware the biases. Clin Chim Acta 2002; 315: 71–97.
   PubMed Web of Science ®Google Scholar
• Regionalt Onkologiskt Centrum i Uppsala/Orebroregio-nen. Prostate cancer registration 1996-2000. Uppsala, Sweden: Regionalt Onkologiskt Centrum i Uppsala/ Orebroregionen, 2002.
   Google Scholar
• Gerard MJ, Frank-Stromborg M. Screening for prostate cancer in asymptomatic men: clinical, legal, and ethical implications. Oncol Nurs Forum 1998; 25: 1561–9.
   PubMedGoogle Scholar
• Peters SM, Jovell AJ, Garcia-Altes A, Serra-Prat M. Screening and clinical management of prostate cancer. A cross-national comparison. Int J Technol Assess Health Care 2001; 17: 215–21.
   Google Scholar
• Carlsson P. Pedersen KV, Varenhorst E. Costs and bene-fits of early detection of prostate cancer. Health Policy 1990; 16: 241–53.
   Google Scholar